Home Immunomic

Immunomic

In operation
-
Nucleic Acid Immunotherapy R&D Provider
Basic
Enterprise Profile

Basic Information

Immunomic is a private clinical-stage biotechnology company dedicated to researching the universal intracellular targeting expression (UNITE) nucleic acid immunotherapy platform. This research technology has the potential to transform the way people use immunotherapy to treat various diseases, including cancer, allergies, and infectious diseases.
Immunomic Therapeutics, Inc.
Maryland,United States of America
15~50 people
January 01, 2005
info@immunomix.com

Enterprise Profile

Industrial Sector
New Drug Development
Technology
Cell Technology Nucleic Acid Technology
Concept
Tumor Therapeutic Products
Application Scenarios
Biologics Innovative Drugs